menu
    • menu

    Find Flibanserin manufacturers, exporters & distributors on PharmaCompass

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    13

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    4

    NDC API

    NDC API

    0

    VMF

    NDC API

    10

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    4

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    1

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    1

    Listed Dossiers

    Listed Dossiers

    7DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    147RELATED EXCIPIENT COMPANIES

    218EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    1

    US Patents

    0

    US Exclusivities

    3

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 915

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    NA

    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    6

    API

    0

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    21

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 167933-07-5, Bimt-17, Bimt 17, Addyi, Ectris, Girosa
    Molecular Formula
    C20H21F3N4O
    Molecular Weight
    390.4  g/mol
    InChI Key
    PPRRDFIXUUSXRA-UHFFFAOYSA-N
    FDA UNII
    37JK4STR6Z
    Flibanserin
    Flibanserin is an orally bioavailable, non-hormonal, multifunctional serotonin agonist and antagonist (MSAA) that may improve sexual desire and arousal in women. Upon oral administration, flibanserin selectively binds to serotonin receptors in the central nervous system, acting as an agonist on 5-HT1A receptors and an antagonist on 5-HT2A receptors. Agonist activity at 5-HT1A postsynaptic receptors may enhance the release of dopamine and other monoamines. Combined with 5-HT2A antagonism, flibanserin boosts levels of dopamine in the mesocortical area of the prefrontal cortex and produces a net increase of norepinephrine selectively in the prefrontal cortex through disinhibition of locus coeruleus noradrenergic neurons. In addition, flibanserin reduces concentrations of serotonin in the prefrontal cortex with chronic administration. Reducing serotonin, which modulates sexual activity in an inhibitory fashion through downstream decreases in dopamine release, while enhancing the release of norepinephrine and dopamine in the prefrontal cortex may improve sexual desire and interest.
    The mechanism of action of flibanserin is as a P-Glycoprotein Inhibitor.
    1 2D Structure

    Flibanserin

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
    2.1.2 InChI
    InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
    2.1.3 InChI Key
    PPRRDFIXUUSXRA-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
    2.2 Other Identifiers
    2.2.1 UNII
    37JK4STR6Z
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1h)-2-one

    2. Addyi

    3. Bimt 17

    4. Bimt-17

    2.3.2 Depositor-Supplied Synonyms

    1. 167933-07-5

    2. Bimt-17

    3. Bimt 17

    4. Addyi

    5. Ectris

    6. Girosa

    7. Bimt 17 Bs

    8. Bimt-17-bs

    9. Filbanserin.

    10. 1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1h-benzo[d]imidazol-2(3h)-one

    11. 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2h-benzimidazol-2-one

    12. 37jk4str6z

    13. Female Viagra [street Name]

    14. 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1h-benzimidazol-2-one

    15. 2h-benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-

    16. 1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1h)-2-one

    17. Female Viagra (street Name)

    18. Flibanserin [usan]

    19. 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2h-benzimidazol-2-one

    20. Flibanserin [usan:inn]

    21. Unii-37jk4str6z

    22. Addyi (tn)

    23. Flibanserin [mi]

    24. Flibanserin [inn]

    25. Flibanserin (usan/inn)

    26. Bimt 17bs

    27. Bimt-17bs

    28. 1-(2-(4-alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone

    29. Flibanserin [mart.]

    30. Flibanserin [who-dd]

    31. Girosa (proposed Trade Name)

    32. Schembl247579

    33. Chembl231068

    34. Gtpl8182

    35. Chebi:90865

    36. Hsdb 8278

    37. Flibanserin [orange Book]

    38. Hms3885k21

    39. Bcp02131

    40. Ex-a2807

    41. Hy-a0095

    42. Bdbm50476735

    43. Mfcd00918402

    44. S3716

    45. Zinc52716421

    46. Akos005146139

    47. Flibanserin; Bimt-17; Bimt-17bs

    48. Am84577

    49. Ccg-268528

    50. Cs-4671

    51. Db04908

    52. 1-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone

    53. 2h-benzimidazol-2-one,1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-

    54. Ncgc00386567-01

    55. Ncgc00386567-02

    56. Ncgc00386567-03

    57. F1239

    58. Ft-0659246

    59. D02577

    60. 933f075

    61. A810922

    62. L001463

    63. Q415996

    64. 1-(2-(4-alpha,alpha,alpha-trifluoro-m-tolyl)-1-(piperazinyl)ethyl)-2-benzimidazolinone

    65. 1-[2-[4-(3-trifluoromethylphenyl)piperazin-1-yl]ethyl]benzimidazol-[1h]-2-one

    66. 3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-1h-benzimidazol-2-one

    67. 1-(2-(4-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone

    68. 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2h-benzimidazol-2-one

    2.4 Create Date
    2006-07-28
    3 Chemical and Physical Properties
    Molecular Weight 390.4 g/mol
    Molecular Formula C20H21F3N4O
    XLogP33.3
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count4
    Exact Mass390.16674579 g/mol
    Monoisotopic Mass390.16674579 g/mol
    Topological Polar Surface Area38.8 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity550
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Therapeutic Uses

    /CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Flibanserin is included in the database.

    NIH/NLM; ClinicalTrials.Gov. Available from, as of September 30, 2015: https://clinicaltrials.gov/search/intervention=FLIBANSERIN%20OR%20BIMT-17

    Addyi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. /Included in US product label/

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    EXPL THER A central problem in the treatment of Parkinson's disease (PD) is the development of motor disturbances like L-DOPA-induced dyskinesia (LID) after long-term treatment. Preclinical and clinical studies demonstrated that serotonin 5-HT(1A) receptor agonists attenuate this disabling motor side effect. The aim of this study was to investigate the ability of flibanserin compared to buspirone to attenuate L-DOPA-sensitized contraversive circling in hemiparkinsonian rats, which is an animal model of LID. Both drugs have a preferential affinity for the serotonin 5-HT(1A) receptors. Buspirone was in comparison because it was expected to have an effect in this model. Unilaterally 6-hydroxydopamine lesioned rats were treated twice daily intraperitoneally (ip) with L-DOPA methylester (12.5 mg/kg) and benserazide (3.25 mg/kg) for 21 days (on days 1, 3, 5, 8, 11, 14, 17 and 21). On day 24, L-DOPA-sensitized rats were treated ip 5 min prior to administration of L-DOPA methyl ester and benserazide with either saline (controls), 2.5, 5 and 10 mg/kg buspirone or flibanserin. Acute administration of both flibanserin and buspirone, dose dependently, attenuated the increased contraversive circling. An almost complete inhibition of the turning response was observed at 5 mg/kg buspirone and 10 mg/kg flibanserin. The current preclinical findings further implicate the 5-HT(1A) receptor as a promising therapeutic target for the reduction of LID and predict a potential efficacy of flibanserin in the treatment of LID in PD.

    PMID:21274579 Gerlach M et al; J Neural Transm 118(12): 1727-32 (2011).

    4.2 Drug Warning

    /BOX WARNING/ The use of Addyi in patients with hepatic impairment increases flibanserin concentrations, which can cause severe hypotension and syncope. Therefore, Addyi is contraindicated in patients with hepatic impairment. Inhibitors are contraindicated in patients taking Addyi.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    /BOX WARNING/ The concomitant use of Addyi and moderate or strong CYP3A4 inhibitors increase s flibanserin concentrations, which can cause severe hypotension and syncope. Therefore, the use of moderate or strong CYP3A4 inhibitors is contraindicated in patients taking Addyi.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    /BOX WARNING/ The use of Addyi and alcohol increases the risk of severe hypotension and syncope. Therefore, alcohol use is contraindicated in patients taking Addyi. Before prescribing Addyi, assess the likelihood of the patient abstaining from alcohol, taking into account the patient's current and past drinking behavior, and other pertinent social and medical history. Counsel patients who are prescribed Addyi about the importance of abstaining from alcohol use. Because of the increased risk of hypotension and syncope due to an interaction with alcohol, Addyi is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Addyi REMS Program.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    Addyi can cause CNS depression (e.g., somnolence, sedation). In five 24-week, randomized, placebo controlled, double-blind trials of premenopausal women with hypoactive sexual desire disorder (HSDD), the incidence of somnolence, sedation or fatigue was 21% and 8% in patients treated with 100 mg Addyi once daily at bedtime and placebo, respectively. The risk of CNS depression is increased if Addyi is taken during waking hours, or if Addyi is taken with alcohol or other CNS depressants, or with medications that increase flibanserin concentrations, such as CYP3A4 inhibitors.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    For more Drug Warnings (Complete) data for Flibanserin (9 total), please visit the HSDB record page.

    4.3 Drug Indication

    For the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

    FDA Label

    Hypoactive Sexual Desire Disorder in Women

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Active Moiety
    FLIBANSERIN
    5.1.2 FDA UNII
    37JK4STR6Z
    5.1.3 Pharmacological Classes
    P-Glycoprotein Inhibitors [MoA]
    5.2 ATC Code

    G - Genito urinary system and sex hormones

    G02 - Other gynecologicals

    G02C - Other gynecologicals

    G02CX - Other gynecologicals

    G02CX02 - Flibanserin

    5.3 Absorption, Distribution and Excretion

    Absorption

    Flibanserin has an absolute oral availability of 33%.

    Route of Elimination

    Elimination via feces (51%) and urine (44%) following a single oral 50 mg dose of flibanserin solution.

    Approximately 98% of the drug is bound to human serum proteins, mainly to albumin.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    Food increased the extent of absorption and slowed the rate of absorption of a 50 mg dose of flibanserin (one half the recommended dosage). Low-, moderate-, and high-fat meals increased flibanserin AUC0-inf by 1.18-, 1.43-, and 1.56-fold; increased Cmax by 1.02-, 1.13-, and 1.15-fold; and prolonged median Tmax to 1.5, 0.9, 1.8 hours from 0.8 hours under fasted conditions, respectively.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    Following oral ministration of a single 100 mg dose of flibanserin in healthy premenopausal women (N=8), mean (SD) Cmax was 419 (206) ng/mL and mean (SD) AUC0-inf was 1543 (511) ng*hr/mL. Median (range) time to reach Cmax was 0.75 (0.75 to 4.0) hours. Absolute bioavailability of flibanserin following oral dosing is 33%.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    /MILK/ Flibanserin is excreted in rat milk. It is unknown whether flibanserin is present in human milk, ... .

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    5.4 Metabolism/Metabolites

    Metabolism is primarily via CYP3A4, slightly CYP2C19. Minimal involvement of CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2D6. At least 35 metabolites of flibanserin are produced, 2 of which reach plasma concentrations as high as parent drug, however they are pharmacologically inactive.

    Flibanserin is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP2C19. Based on in vitro and/or in vivo data, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 contribute minimally to the metabolism of flibanserin. After a single oral solution dose of 50 mg 14C-radiolabeled flibanserin, 44% of the total 14C-flibanserin related radioactivity was recovered in urine, and 51% was recovered in feces. Flibanserin is extensively metabolized to at least 35 metabolites, most of them occurring in low concentrations in plasma. Two metabolites could be characterized that showed plasma concentrations similar to that achieved with flibanserin: 6,21-dihydroxy-flibanserin-6,21-disulfate and 6-hydroxy-flibanserin-6-sulfate. These two metabolites are inactive.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    5.5 Biological Half-Life

    11 hours

    Flibanserin has a mean terminal half-life of approximately 11 hours.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    5.6 Mechanism of Action

    Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.

    Flibanserin has preferential affinity for serotonin 5-HT(1A), dopamine D(4k), and serotonin 5-HT(2A) receptors. In vitro and in microiontophoresis, flibanserin behaves as a 5-HT(1A) agonist, a very weak partial agonist on dopamine D(4) receptors, and a 5-HT(2A) antagonist. In vivo flibanserin binds equally to 5-HT(1A) and 5-HT(2A) receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT(2A) receptors in higher proportion than 5-HT(1A) receptors. The effects of flibanserin on adenylyl cyclase are different from those of buspirone and 8-OH-DPAT, two other purported 5-HT(1A) receptor agonists. Flibanserin reduces neuronal firing rate in cells of the dorsal raphe, hippocampus, and cortex with the CA1 region being the most sensitive in the brain. Flibanserin-induced reduction in firing rate in the cortex seems to be mediated through stimulation of postsynaptic 5-HT(1A) receptors, whereas the reduction of the number of active cells seems to be mediated through dopamine D(4) receptor stimulation. Flibanserin quickly desensitizes somatic 5-HT autoreceptors in the dorsal raphe and enhances tonic activation of postsynaptic 5-HT(1A) receptors in the CA3 region. Flibanserin preferentially reduces synthesis and extracellular levels of 5-HT in the cortex, where it enhances extracellular levels of NE and DA. Flibanserin displays antidepressant-like activity in most animal models sensitive to antidepressants. Such activity, however, seems qualitatively different from that exerted by other antidepressants. Flibanserin seems to act via direct or indirect stimulation of 5-HT(1A), DA, and opioid receptors in those animal models. Flibanserin does not display consistent effects in animal models of anxiety and seems to exert potential antipsychotic effects. Flibanserin may induce some sedation but does not induce observable toxic effects at pharmacologically relevant doses.

    PMID:12177684 Borsini F et al; CNS Drug Rev 8(2): 117-42 (2002).

    Flibanserin is a novel pharmacologic agent in late-stage clinical testing for hypoactive sexual desire disorder (HSDD) in premenopausal women. A literature review was conducted of all published works on flibanserin and on related studies of serotonin (5-HT)(1A) receptors and 5-HT(2A) receptors, including their actions on monoamines and on sexual function. At clinically relevant doses, flibanserin acts predominantly at 5-HT(1A) receptors as an agonist and secondarily at 5-HT(2A) receptors as an antagonist. Additional binding actions within an order of magnitude of its 5-HT(1A) affinity, which are not likely to be clinically relevant, include weaker antagonist actions at 5-HT(2C) and 5-HT(2B) receptors, and less defined activity at dopamine (DA) D4 receptors. The 5-HT(1A) actions of flibanserin are only seen postsynaptically, which is unlike other agents such as buspirone that act at presynaptic 5-HT(1A) receptors. Furthermore, the postsynaptic actions of chronic flibanserin administration appear to demonstrate a preference for some populations of postsynaptic 5-HT receptors, particularly those that are located on the prefrontal cortex (PFC) pyramidal neurons, which regulate monoamine release in certain selective brain regions. The regional selectivity of flibanserin results in a unique pattern of monoamine modulation. Sustained increases in baseline of DA and norepinephrine (NE) are observed in the PFC, and flibanserin dosing increases DA and NE levels above the basal changes. Conversely, flibanserin induces transient decreases in 5-HT levels in some brain areas such as the PFC, nucleus accumbens, and hypothalamus, but not in other brain areas such as the hippocampus. Therefore, since DA and NE are excitatory and 5-HT is inhibitory to sexual desire and arousal, it is tempting to postulate that the actions of flibanserin on serotonin receptors at the PFC pyramidal neurons, resulting in increased DA and NE yet reduced 5-HT in the PFC, are the mechanistic underpinnings of enhancing sexual desire in HSDD.

    PMID:20840530 Stahl SM et al; J Sex Med 8(1):15-27 (2011).

    In vitro, flibanserin demonstrated high affinity for the following serotonin (5-hydroxytryptamine or 5-T) receptors: agonist activity at 5-HT1A and antagonist activity at 5-HT2A. Flibanserin also has moderate antagonist activities at the 5-HT2B, 5-HT2C, and dopamine D4 receptors.

    NIH; DailyMed. Current Medication Information for Addyi (Flibanserin) Tablet, Film Coated (Updated: August 2015). Available from, as of November 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3819daf3-e935-2c53-c527-e1d57922f394

    API SUPPLIERS

    read-more
    read-more

    01

    Century Pharmaceuticals

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India
    Booth #2.F34
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCentury has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Century Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ChemExpress

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Apicore

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    Apicore

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 35336

    Submission : 2020-11-12

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Aktinos

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    Aktinos

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 73223-006

    Start Marketing Date : 2019-10-31

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Rakshit Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    Rakshit Drugs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Symed Labs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    Symed Labs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2025-09-29

    Valid Till : 2028-08-09

    Written Confirmation Number : WC-0072

    Address of the Firm :

    NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    AASraw Biochemical Technology Co.,...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    AASraw Biochemical Technology Co.,...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Country

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 87142-167

    Start Marketing Date : 2025-10-24

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Beloorbayir Biotech

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    Beloorbayir Biotech

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Hangzhou Longshine Bio-Tech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    The Pharmacy Technology
    Not Confirmed
    arrow

    Hangzhou Longshine Bio-Tech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    The Pharmacy Technology
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-moreread-more

    01

    Apicore Llc

    India

    USDMF

    arrow
    COMPAMED
    Not Confirmed

    01

    Apicore Llc

    India
    arrow
    COMPAMED
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 35336

    Submission : 2020-11-12

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Century Pharmaceuticals

    India
    arrow
    CPhI India
    Booth #2.F34
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCentury has been an API manufacturer for over 40 years & is the partner of choice for multipurpose custom manufacturing projects.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : Century Pharmaceuticals, established in 1982, has 40 years of experience in manufacturing APIs. It has been supplying APIs produced in-house to several major pharma companies in In...

    Century Pharmaceuticals, established in 1982, has 40 years of experience in manufacturing APIs. It has been supplying APIs produced in-house to several major pharma companies in India and abroad. Its APIs are manufactured in accordance with cGMP, 21CFR part 10 and ICH guidelines. It also produces intermediates and develops new APIs as per the needs of its clients. Century conducts biotechnological research that focuses on human therapeutic proteins. Currently, research is underway to find treatments for asthma, mastocytosis and basophilic leukemia. Century supplies research-grade biotech products and a wide range of animal health products.
    Century Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ChemExpress

    China
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and new modalities such as...

    Founded in 2006, ChemExpress specializes in offering CRO & CDMO services for pharmaceutical and biotech companies, focusing on small molecules, biologics and new modalities such as ADCs/XDCs, peptides and PROTACs. Our comprehensive platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products (solid & semi-solid, biologics liquid & lyophilized). We support our clients' projects from early drug discovery, process development to commercialization.
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    AASraw Biochemical Technology Co., ...

    China
    COMPAMED
    Not Confirmed
    arrow

    AASraw Biochemical Technology Co., ...

    China
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    flibanserin

    About the Company : Aasraw Biochemical Technology Co.,ltd was reorganized by a Shanghai based Biochemical Engineering Laboratory in 2008, which was built by 5 Chinese Ph. Doctors, who are majored at C...

    Aasraw Biochemical Technology Co.,ltd was reorganized by a Shanghai based Biochemical Engineering Laboratory in 2008, which was built by 5 Chinese Ph. Doctors, who are majored at Chemical Engineering in University of Tulsa, Oklahoma, USA. The new born AASraw gained more investment and attracted more top genius guys in the biochemical industry. There are more advantaged equipment and instruments to be being adopted for analyzing, testing, Synthesis, etc., for example, DSC, GV, HPLC, UV, RV, etc. Till now, there are more than 20 key technology engineers. The fixed assets is more than USD30 million.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Aktinos

    India
    COMPAMED
    Not Confirmed
    arrow

    Aktinos

    India
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : Aktinos is an innovation-driven, people-centric and client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical indu...

    Aktinos is an innovation-driven, people-centric and client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry. Aktinos provides Contract Research and Manufacturing Services (CRAMS) with an emphasis on process development, scale-up products from lowcost providers with world-class standards.The strong analytical chemistry team at Aktinos works closely with the Chemical Development and tech-transfer teams as the process evolves. We are innovative, unconventional, visionary and bold.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Apicore

    India
    COMPAMED
    Not Confirmed
    arrow

    Apicore

    India
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide p...

    Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide portfolio of services ranging from API’s for the generic industry to custom synthesis for early phase pharmaceutical research and branded products. Our USFDA approved facilities in India (Visakhapatnam, Andhra Pradesh and Vadodara, Gujarat) are both equipped with state-of-the-art analytical and research capabilities. While our worldwide network of locations seamlessly integrate with each other, each unit also independently houses a full
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Beloorbayir Biotech

    India
    COMPAMED
    Not Confirmed
    arrow

    Beloorbayir Biotech

    India
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : The company is in the business of manufacturing and marketing botanical extracts and nutraceuticals formulations to both domestic and global customers. The products include health/...

    The company is in the business of manufacturing and marketing botanical extracts and nutraceuticals formulations to both domestic and global customers. The products include health/dietary supplements for improving the overall wellness/prevention of diseases, ingredients for functional foods, food colors, and extracts. The company exports to around 35 countries in Europe, US, and Japan, with strong relations with global majors. The company has production facilities near Bengaluru (Peenya, Tumkur, Bidadi), Bhatkal, Hyderabad and Pune.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Hangzhou Longshine Bio-Tech

    China
    COMPAMED
    Not Confirmed
    arrow

    Hangzhou Longshine Bio-Tech

    China
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    flibanserin

    About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...

    Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, catering to both export and import markets. The company consists of two primary business departments: the Professional Sourcing/Product Team and the Quality Team. Backed by experienced partners, Longshine has evolved into a trustworthy supplier of high-quality products and received ISO9001:2008 certification in 2017.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Rakshit Drugs

    India
    COMPAMED
    Not Confirmed
    arrow

    Rakshit Drugs

    India
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : Rakshit is an integrated API manufacturing company. Established in 2000. Today Rakshit has emerged a dependable and strong manufacturer of key APIs & intermediates for global marke...

    Rakshit is an integrated API manufacturing company. Established in 2000. Today Rakshit has emerged a dependable and strong manufacturer of key APIs & intermediates for global markets. Focusing on its activities in R&D as well as building up newer facilities/ capacities to catch up with increasing demand year after year. Rakshit group has 4 cGMP compliance Manufacturing Facilities spread over Andhra Pradesh & Telangana states of India. Supplying its products to all over the globe from US, Europe, Japan, Asia & to Latin America. Rakshit facilities are approved by the regulatory authorities like, USFDA, Japan PMDA, Korea-MFDS, CDSCO-India.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Symed Labs

    India
    COMPAMED
    Not Confirmed
    arrow

    Symed Labs

    India
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : Symed Labs Ltd is a leading Hyderabad based manufacturer of Active Pharmaceutical Ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry for chemist...

    Symed Labs Ltd is a leading Hyderabad based manufacturer of Active Pharmaceutical Ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry for chemistry related services. We are more than 300 employees strong and our core competence is in the application of strong process chemistry to manufacturing in a regulatory environment. For the past 15 years, Symed has been at the forefront of facilitating and accelerating drug development (and GMP manufacturing) of APIs. The company's technical and scientific teams provide reliable solutions and services to the global pharmaceutical industry.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Viyash Life Sciences

    India
    COMPAMED
    Not Confirmed
    arrow

    Viyash Life Sciences

    India
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Flibanserin

    About the Company : Viyash, true to its name, literally represents honesty and leadership in every sense. We are an integrated pharmaceutical company with a strong portfolio of niche formulations, ...

    Viyash, true to its name, literally represents honesty and leadership in every sense. We are an integrated pharmaceutical company with a strong portfolio of niche formulations, APIs and advanced intermediates Viyash and its subsidiaries operate 10 API / Intermediate facilities with a combined capacity ~2000 KL and diversified capabilities in every aspect - small / large volume, potent / non-potent, regulated / semi-regulated markets. In addition, we also operate one formulation manufacturing facility in New Jersey, USA with a capacity of ~ 1.2 Bn units.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649183400,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734","city":"HYDERABAD","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"UNDISCLOSED","customerCountry":"BANGLADESH","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"1300","totalValueFC":"1272.4","currency":"USD","unitRateINR":96000,"date":"06-Apr-2022","totalValueINR":"96000","totalValueInUsd":"1272.4","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"9508225","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652985000,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734","city":"HYDERABAD","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"AL ARAFAH ISLAMI BANK LTD","customerCountry":"BANGLADESH","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"980","totalValueFC":"9717.2","currency":"USD","unitRateINR":75100,"date":"20-May-2022","totalValueINR":"751000","totalValueInUsd":"9717.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"1535949","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"425\/3 RT D NO 7-1-621\/328, S.R.NAGAR Contact No: 919177739734, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669314600,"product":"FLIBANSERIN (TAX INVOICE NO:22-23\/EXP-72","address":"H.NO. 8-2-293\/174\/3, ROAD NO. 14,, B.N. REDDY COLONY, BANJARA HILLS,","city":"HYDERABAD,TELANGANA","supplier":"SYMED LABS LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"BEACON PHARMACEUTICALS LTD","customerCountry":"BANGLADESH","quantity":"0.80","actualQuantity":"0.8","unit":"KGS","unitRateFc":"937.5","totalValueFC":"686.2","currency":"USD","unitRateINR":70000,"date":"25-Nov-2022","totalValueINR":"56000","totalValueInUsd":"686.2","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5729340","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO. 8-2-293\/174\/3, ROAD NO. 14,, B.N. REDDY COLONY, BANJARA HILLS,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1672857000,"product":"FLIBANSERIN (ALONG WITH SENDING FREE SAM","address":"SRI LAKSHMI SPACES 5TH FLOOR,PLOT NO 7 BLOCK NO B KAVURI HILLS","city":"MADHAPUR HYDERABAD,TELANGANA","supplier":"AKTINOS PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"AGP LTD","customerCountry":"PAKISTAN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"3750","totalValueFC":"3693.8","currency":"USD","unitRateINR":302000,"date":"05-Jan-2023","totalValueINR":"302000","totalValueInUsd":"3693.8","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"6717260","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"SRI LAKSHMI SPACES 5TH FLOOR,PLOT NO 7 BLOCK NO B KAVURI HILLS, MADHAPUR HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1695234600,"product":"FLIBANSERIN (TAX INVOICE NO:23-24\/EXP-497, DT:12-09-2023)","address":"8-3-166\/6 7, IIND FLOOR,SREE ARCADE","city":"HYDERABAD-AP","supplier":"SYMED LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"UNDISCLOSED","customerCountry":"TURKEY","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"2535","totalValueFC":"2481.7","currency":"USD","unitRateINR":206000,"date":"21-Sep-2023","totalValueINR":"206000","totalValueInUsd":"2481.7","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4082489","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/6 7, IIND FLOOR,SREE ARCADE, HYDERABAD-AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706812200,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"MUTUAL TRUST BANK P","customerCountry":"BANGLADESH","quantity":"20.00","actualQuantity":"20","unit":"KGS","unitRateFc":"725","totalValueFC":"15286.2","currency":"EURO","unitRateINR":63417.5,"date":"02-Feb-2024","totalValueINR":"1268350","totalValueInUsd":"15286.2","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"7219921","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725474600,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"WORLD MEDICINE ILAC SAN VETIC A","customerCountry":"TURKEY","quantity":"56.00","actualQuantity":"56","unit":"KGS","unitRateFc":"1350","totalValueFC":"74769.7","currency":"USD","unitRateINR":111889.09660714286,"date":"05-Sep-2024","totalValueINR":"6265789.41","totalValueInUsd":"74769.7","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"3786023","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729103400,"product":"FLIBANSERIN ( TAX INVOICE NO :24-25\/EXP-631 DT :09.10.2024)","address":"8-3-166\/6 7, IIND FLOOR,SREE ARCADE","city":"HYDERABAD-AP","supplier":"SYMED LABS LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"NOBIS SCIENTIFIC ILAC SANAYL VE TIC","customerCountry":"TURKEY","quantity":"23.00","actualQuantity":"23","unit":"KGS","unitRateFc":"1150","totalValueFC":"26034.5","currency":"USD","unitRateINR":95112.608695652176,"date":"17-Oct-2024","totalValueINR":"2187590","totalValueInUsd":"26034.5","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"4905955","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/6 7, IIND FLOOR,SREE ARCADE, HYDERABAD-AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739989800,"product":"PHARMACEUTICAL RAW MATERIAL - FLIBANSERIN (CAS NO. 167933-07-5)","address":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,","city":"VADODARA GUJ.","supplier":"CENTURY PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"ISLAMABAD - ISLAMABA","customer":"TO ORDER","customerCountry":"PAKISTAN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"1660","totalValueFC":"1490.5","currency":"USD","unitRateINR":129622.58,"date":"20-Feb-2025","totalValueINR":"129622.58","totalValueInUsd":"1490.5","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"8333489","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"406,WORLD TRADE CENTRE,SAYAJIGUNJ,, VADODARA GUJ.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1740421800,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"EASTERN BANK PLC","customerCountry":"BANGLADESH","quantity":"25.00","actualQuantity":"25","unit":"KGS","unitRateFc":"800","totalValueFC":"19651.8","currency":"USD","unitRateINR":68360,"date":"25-Feb-2025","totalValueINR":"1709000","totalValueInUsd":"19651.8","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"8482383","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1751221800,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"THREESIXTY FREIGHT FORWARDING LLC","customerCountry":"UNITED ARAB EMIRATES","quantity":"50.00","actualQuantity":"50","unit":"KGS","unitRateFc":"1235.5","totalValueFC":"70066.7","currency":"USD","unitRateINR":120410.125,"date":"30-Jun-2025","totalValueINR":"6020506.25","totalValueInUsd":"70066.7","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"3153677","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q4","strtotime":1761676200,"product":"FLIBANSERIN","address":"425\/3 RT D NO 7-1-621\/328,","city":"HYDERABAD.AP","supplier":"RAKSHIT PHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"CNHKG","customer":"UNDISCLOSED","customerCountry":"CHINA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"940","totalValueFC":"9178.2","currency":"USD","unitRateINR":81108.5,"date":"29-Oct-2025","totalValueINR":"811085","totalValueInUsd":"9178.2","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"6496066","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"425\/3 RT D NO 7-1-621\/328,, HYDERABAD.AP","customerAddress":""}]
    06-Apr-2022
    29-Oct-2025
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study Shows Positive Preliminary Results of Flibanserin in Breast Cancer Patients Suffering from Low Libido

    Details:

    The baseline means Female Sexual Function Index (FSFI) score was 13.3, with FSFI- desire score of 1.96 after 8 weeks on Addyi (flibanserin), an FDA-approved non-hormonal pill mean FSFI total score increased to 19.4, and the mean FSFI-d score increased to 3.3.


    Lead Product(s): Flibanserin,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Addyi

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 15, 2022

    blank

    01

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study Shows Positive Preliminary Results of Flibanserin in Breast Cancer Patients Suffering from L...

    Details : The baseline means Female Sexual Function Index (FSFI) score was 13.3, with FSFI- desire score of 1.96 after 8 weeks on Addyi (flibanserin), an FDA-approved non-hormonal pill mean FSFI total score increased to 19.4, and the mean FSFI-d score increased to...

    Product Name : Addyi

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 15, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (...

    Details:

    Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Flibanserin,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Biomed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 31, 2020

    blank

    02

    Genuine Research Center, Egypt

    Country
    arrow
    COMPAMED
    Not Confirmed

    Genuine Research Center, Egypt

    Country
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Biomed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Ind...

    Details : Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    July 31, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Hypoactive Sexual Desire Disorder in Males

    Details:

    Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Libido.


    Lead Product(s): Flibanserin,Inapplicable

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Mohit Khera

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 28, 2019

    blank

    03

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin,Inapplicable

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Mohit Khera

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hypoactive Sexual Desire Disorder in Males

    Details : Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Libido.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    June 28, 2019

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

    Details:

    Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sexual Dysfunctions, Psychological.


    Lead Product(s): Flibanserin,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 25, 2010

    blank

    04

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HS...

    Details : Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sexual Dysfunctions, Psychological.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    August 25, 2010

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers

    Details:

    Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Flibanserin,Digoxin

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 02, 2010

    blank

    05

    Boehringer Ingelheim GmbH

    Germany
    arrow
    COMPAMED
    Not Confirmed

    Boehringer Ingelheim GmbH

    Germany
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin,Digoxin

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 m...

    Details : Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    June 02, 2010

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

    Details:

    Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sexual Dysfunctions, Psychological.


    Lead Product(s): Flibanserin,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 14, 2010

    blank

    06

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desi...

    Details : Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sexual Dysfunctions, Psychological.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 14, 2010

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

    Details:

    Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sexual Dysfunctions, Psychological.


    Lead Product(s): Flibanserin,Inapplicable

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 28, 2010

    blank

    07

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed

    Sprout Pharma

    U.S.A
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Flibanserin,Inapplicable

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in Nort...

    Details : Flibanserin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sexual Dysfunctions, Psychological.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 28, 2010

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Dossiers

    read-more
    read-more

    01

    Tobio Novelfarma

    Turkey
    COMPAMED
    Not Confirmed
    arrow

    Tobio Novelfarma

    Turkey
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Turkey
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Bioequivalent to ADDYI

    Registration Country : Turkey

    Flibanserin

    Brand Name : PINKALL

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100MG

    Packaging : 30 Tablets/Bottle

    Approval Date :

    Application Number :

    Regulatory Info : Bioequivalent to ADDYI

    Registration Country : Turkey

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    01

    Tobio Novelfarma

    Turkey
    COMPAMED
    Not Confirmed
    arrow

    Tobio Novelfarma

    Turkey
    arrow
    COMPAMED
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Turkey
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging : 30 Tablets/Bottle

    Regulatory Info : Bioequivalent to ADDYI

    Flibanserin

    Dosage : Film Coated Tablet

    Dosage Strength : 100MG

    Brand Name : PINKALL

    Approval Date :

    Application Number :

    Registration Country : Turkey

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Granulation

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Topical

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 167933-07-5 / Flibanserin API manufacturers, exporters & distributors?

    Flibanserin manufacturers, exporters & distributors 1

    65

    PharmaCompass offers a list of Flibanserin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Flibanserin manufacturer or Flibanserin supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Flibanserin manufacturer or Flibanserin supplier.

    PharmaCompass also assists you with knowing the Flibanserin API Price utilized in the formulation of products. Flibanserin API Price is not always fixed or binding as the Flibanserin Price is obtained through a variety of data sources. The Flibanserin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Flibanserin

    Synonyms

    167933-07-5, Bimt-17, Bimt 17, Addyi, Ectris, Girosa

    Cas Number

    167933-07-5

    Unique Ingredient Identifier (UNII)

    37JK4STR6Z

    About Flibanserin

    Flibanserin is an orally bioavailable, non-hormonal, multifunctional serotonin agonist and antagonist (MSAA) that may improve sexual desire and arousal in women. Upon oral administration, flibanserin selectively binds to serotonin receptors in the central nervous system, acting as an agonist on 5-HT1A receptors and an antagonist on 5-HT2A receptors. Agonist activity at 5-HT1A postsynaptic receptors may enhance the release of dopamine and other monoamines. Combined with 5-HT2A antagonism, flibanserin boosts levels of dopamine in the mesocortical area of the prefrontal cortex and produces a net increase of norepinephrine selectively in the prefrontal cortex through disinhibition of locus coeruleus noradrenergic neurons. In addition, flibanserin reduces concentrations of serotonin in the prefrontal cortex with chronic administration. Reducing serotonin, which modulates sexual activity in an inhibitory fashion through downstream decreases in dopamine release, while enhancing the release of norepinephrine and dopamine in the prefrontal cortex may improve sexual desire and interest.

    Flibanserin Manufacturers

    A Flibanserin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flibanserin, including repackagers and relabelers. The FDA regulates Flibanserin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flibanserin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Flibanserin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Flibanserin Suppliers

    A Flibanserin supplier is an individual or a company that provides Flibanserin active pharmaceutical ingredient (API) or Flibanserin finished formulations upon request. The Flibanserin suppliers may include Flibanserin API manufacturers, exporters, distributors and traders.

    click here to find a list of Flibanserin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Flibanserin USDMF

    A Flibanserin DMF (Drug Master File) is a document detailing the whole manufacturing process of Flibanserin active pharmaceutical ingredient (API) in detail. Different forms of Flibanserin DMFs exist exist since differing nations have different regulations, such as Flibanserin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Flibanserin DMF submitted to regulatory agencies in the US is known as a USDMF. Flibanserin USDMF includes data on Flibanserin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Flibanserin USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Flibanserin suppliers with USDMF on PharmaCompass.

    Flibanserin WC

    A Flibanserin written confirmation (Flibanserin WC) is an official document issued by a regulatory agency to a Flibanserin manufacturer, verifying that the manufacturing facility of a Flibanserin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Flibanserin APIs or Flibanserin finished pharmaceutical products to another nation, regulatory agencies frequently require a Flibanserin WC (written confirmation) as part of the regulatory process.

    click here to find a list of Flibanserin suppliers with Written Confirmation (WC) on PharmaCompass.

    Flibanserin NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Flibanserin as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Flibanserin API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Flibanserin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Flibanserin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Flibanserin NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Flibanserin suppliers with NDC on PharmaCompass.

    Flibanserin GMP

    Flibanserin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Flibanserin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flibanserin GMP manufacturer or Flibanserin GMP API supplier for your needs.

    Flibanserin CoA

    A Flibanserin CoA (Certificate of Analysis) is a formal document that attests to Flibanserin's compliance with Flibanserin specifications and serves as a tool for batch-level quality control.

    Flibanserin CoA mostly includes findings from lab analyses of a specific batch. For each Flibanserin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Flibanserin may be tested according to a variety of international standards, such as European Pharmacopoeia (Flibanserin EP), Flibanserin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flibanserin USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search